The Global Health Body Sounds Concern Over Critical Scarcity of Obesity Medications

Fewer than a tenth of people who could benefit from GLP-1 drugs including Wegovy can access them, caution the global health agency as it releases its initial guidance on the drugs.

Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for increased and just availability to GLP-1 medication.

Per forecasts, over two billion are projected to be obese by 2030 unless action is taken.

"The new guidelines affirms that obesity is a chronic disease that can be managed with thorough and ongoing care," said its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major hurdles to broad availability to the injections that can aid individuals in losing significant weight, notes the body.

Skinny Jab Scarcity

Even under the current most favorable outlook, the supply of such drugs would only suffice for around 100 million people – under 10% of the global need, as stated by the WHO.

The advice calls on governments and firms to expand availability, by approaches including licensing agreements.

Exclusive production rights on semaglutide – the main component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.

The Way Obesity Jabs Operate

These medications replicate a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so users eat less.

Patients commonly see weight reduction after several weeks of starting on the weekly injections.

Studies suggests users may regain a significant portion a year later of discontinuing the treatment, as their normal appetite come back.

Being overweight or obese elevates your chance for developing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity affects individuals in all nations and was responsible for millions of fatalities worldwide in 2024, as per the health agency.